Welcome to our dedicated page for Emergent Biosolutions SEC filings (Ticker: EBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Emergent BioSolutions Inc. (NYSE: EBS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a New York Stock Exchange‑listed pharmaceutical preparation manufacturing company, Emergent submits annual reports on Form 10‑K, quarterly reports on Form 10‑Q and current reports on Form 8‑K that describe its operations, financial condition and material events.
In its recent Form 8‑K filings, Emergent has reported topics such as quarterly financial and operating results, voluntary prepayment under a term loan facility, contract modifications and options for medical countermeasures, regulatory approvals for manufacturing changes, and changes in board membership. These current reports often incorporate press releases and presentation materials by reference, giving additional detail on product revenues, segment performance and government contract activity.
Filings also confirm that Emergent’s common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol EBS. Disclosures identify its reportable segments, including Commercial Products and MCM Products, and describe how Services and contracts and grants revenues are presented. Other events filings outline contract modifications with agencies such as the Administration for Strategic Preparedness and Response and BARDA for products including ACAM2000®, CYFENDUS™, BioThrax® and BAT®.
On Stock Titan, investors can review these SEC documents alongside AI‑generated summaries that highlight key points from lengthy filings. Real‑time updates from EDGAR surface new 10‑K and 10‑Q reports as they are filed, while Form 8‑K items flag significant developments in financing, contracts, regulatory approvals and governance. Users can also track how Emergent describes its medical countermeasures portfolio, naloxone products and segment structure over time through its official regulatory language.
Emergent BioSolutions Inc. reported that its president and chief executive officer, Joseph C. Papa, is presenting at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company made available an investor presentation, furnished as Exhibit 99.1 to this Form 8-K, which contains the slides used for the event.
The information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, so it is not subject to liability under Section 18 of the Exchange Act and is not automatically incorporated into Securities Act or Exchange Act filings unless specifically stated otherwise.
Emergent BioSolutions Inc. disclosed that it voluntarily prepaid $100 million in late December 2025 on its outstanding term loan under a credit agreement dated August 30, 2024. This early repayment reduces the company’s term loan balance and interest-bearing debt under that facility. The company announced the prepayment in a press release furnished as an exhibit, indicating a proactive step in managing its capital structure and obligations to its lenders.
An insider of EBS has filed a Rule 144 notice to sell 25,748 common shares. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $360,142.43, and the issuer has 52,519,964 common shares outstanding.
The 25,748 shares were acquired from the issuer on 01/07/2026 via a stock option exercise paid in cash on the same date. The filing also reports that Louis W Sullivan sold 104,695 common shares during the past three months for gross proceeds of $1,336,462.98.
EBS has filed a notice under Rule 144 for a proposed sale of 104,695 shares of common stock, with an aggregate market value of $1,336,462.98. These shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE, with an approximate sale date of 12/22/2025. The issuer had 52,519,964 shares of common stock outstanding, providing context for the size of this planned sale. The securities being sold were originally acquired as restricted stock on 05/18/2016 and as exercised shares on 05/10/2021, both from the issuer.
Emergent BioSolutions reported an insider transaction by an officer serving as senior vice president of R&D and chief medical officer. On December 14, 2025, 3,543 shares of common stock were withheld at a price of $11.41 per share to pay taxes due when restricted stock units vested and settled.
After this tax withholding, the officer directly beneficially owns 88,439 shares of Emergent BioSolutions common stock.
Emergent BioSolutions Inc. announced that it has received approval from the U.S. Food and Drug Administration for drug product manufacturing of raxibacumab at its Winnipeg manufacturing site. This means the company is now authorized to produce this product at that facility, which supports its medical countermeasures business focused on serious public health threats. The update was shared through a press release furnished as an exhibit, and the information is presented as a Regulation FD disclosure rather than as part of the company’s audited financial statements.
Emergent BioSolutions director reported multiple stock transactions in the company’s shares. On December 5, 2025, the director exercised 25,748 stock options at an exercise price of $5.02 per share, receiving the same number of common shares. To cover the option exercise price and applicable taxes, 10,864 shares were sold, with additional open‑market sales of 7,100 shares at a weighted average price of $12.1113 and 14,884 shares at a weighted average price of $11.8978. After these transactions, the director held 98,417 shares of common stock directly and no remaining derivative securities from this option grant.
EBS reported a planned insider sale under Rule 144. A company affiliate intends to sell 32,848 shares of common stock, with an aggregate market value of $392,334.78, through Morgan Stanley Smith Barney LLC on the NYSE around 12/05/2025. The issuer has 52,519,964 shares outstanding, providing context for the size of this transaction.
The shares come from a mix of restricted stock awards granted between 2021 and 2022 and a stock option exercise for 25,748 shares paid in cash on 12/05/2025. By signing the notice, the seller represents that they are not aware of any material adverse information about EBS’s current or prospective operations that has not been publicly disclosed.
Emergent BioSolutions (EBS) reported an insider transaction on a Form 4 for its SVP, Bioservices. On 11/11/2025, 610 shares of common stock were withheld under transaction code F, which represents shares withheld to cover taxes upon the vesting and settlement of restricted stock units. The shares were valued at $10.88 for withholding purposes. Following this administrative transaction, the officer directly beneficially owns 103,082 shares of EBS common stock.
Emergent BioSolutions (EBS) — Form 4 insider transaction. A director reported selling 17,801 shares of common stock on 11/10/2025 at a weighted average price of $10.54, with trade prices ranging from $10.33 to $10.79. The sale was executed under a Rule 10b5-1 trading plan dated August 11, 2025, established to cover tax obligations from RSUs that vested on October 2, 2025. Following the transaction, the reporting person beneficially owns 119,858 shares.
FAQ
What is the current stock price of Emergent Biosolutions (EBS)?
What is the market cap of Emergent Biosolutions (EBS)?
